175 related articles for article (PubMed ID: 15254428)
1. Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib.
Schroeder CP; Yang P; Newman RA; Lotan R
Cancer Biol Ther; 2004 Sep; 3(9):847-52. PubMed ID: 15254428
[TBL] [Abstract][Full Text] [Related]
2. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
Hashitani S; Urade M; Nishimura N; Maeda T; Takaoka K; Noguchi K; Sakurai K
Int J Oncol; 2003 Sep; 23(3):665-72. PubMed ID: 12888902
[TBL] [Abstract][Full Text] [Related]
3. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib.
Li N; Sood S; Wang S; Fang M; Wang P; Sun Z; Yang CS; Chen X
Clin Cancer Res; 2005 Mar; 11(5):2089-96. PubMed ID: 15756036
[TBL] [Abstract][Full Text] [Related]
5. Effects of celecoxib treatment over the AKT pathway in head and neck squamous cell carcinoma.
Abrahão AC; Giudice FS; Sperandio FF; Pinto Junior Ddos S
J Oral Pathol Med; 2013 Nov; 42(10):793-8. PubMed ID: 23679684
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases.
Attiga FA; Fernandez PM; Weeraratna AT; Manyak MJ; Patierno SR
Cancer Res; 2000 Aug; 60(16):4629-37. PubMed ID: 10969817
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitous expression of cyclooxygenase-2 in meningiomas and decrease in cell growth following in vitro treatment with the inhibitor celecoxib: potential therapeutic application.
Ragel BT; Jensen RL; Gillespie DL; Prescott SM; Couldwell WT
J Neurosurg; 2005 Sep; 103(3):508-17. PubMed ID: 16235684
[TBL] [Abstract][Full Text] [Related]
8. Tumor-associated down-regulation of 15-lipoxygenase-1 is reversed by celecoxib in colorectal cancer.
Heslin MJ; Hawkins A; Boedefeld W; Arnoletti JP; Frolov A; Soong R; Urist MM; Bland KI
Ann Surg; 2005 Jun; 241(6):941-6; discussion 946-7. PubMed ID: 15912043
[TBL] [Abstract][Full Text] [Related]
9. Modification of eicosanoid profile in human blood treated by dual COX/LOX inhibitors.
Pommery J; Pommery N; Hénichart JP
Prostaglandins Leukot Essent Fatty Acids; 2005 Dec; 73(6):411-7. PubMed ID: 16213697
[TBL] [Abstract][Full Text] [Related]
10. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.
Patel MI; Subbaramaiah K; Du B; Chang M; Yang P; Newman RA; Cordon-Cardo C; Thaler HT; Dannenberg AJ
Clin Cancer Res; 2005 Mar; 11(5):1999-2007. PubMed ID: 15756026
[TBL] [Abstract][Full Text] [Related]
11. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
Chen Z; Zhang X; Li M; Wang Z; Wieand HS; Grandis JR; Shin DM
Clin Cancer Res; 2004 Sep; 10(17):5930-9. PubMed ID: 15355926
[TBL] [Abstract][Full Text] [Related]
12. Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo.
Zhao Y; Hao Y; Ji H; Fang Y; Guo Y; Sha W; Zhou Y; Pang X; Southerland WM; Califano JA; Gu X
Cancer Prev Res (Phila); 2010 Jun; 3(6):787-96. PubMed ID: 20501859
[TBL] [Abstract][Full Text] [Related]
13. Celecoxib inhibits cell proliferation through the activation of ERK and p38 MAPK in head and neck squamous cell carcinoma cell lines.
Park SW; Kim HS; Hah JW; Jeong WJ; Kim KH; Sung MW
Anticancer Drugs; 2010 Oct; 21(9):823-30. PubMed ID: 20717005
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis.
Gallo O; Franchi A; Magnelli L; Sardi I; Vannacci A; Boddi V; Chiarugi V; Masini E
Neoplasia; 2001; 3(1):53-61. PubMed ID: 11326316
[TBL] [Abstract][Full Text] [Related]
15. Activation of diverse eicosanoid pathways in osteoarthritic cartilage: a lipidomic and genomic analysis.
Attur M; Dave M; Abramson SB; Amin A
Bull NYU Hosp Jt Dis; 2012; 70(2):99-108. PubMed ID: 22891999
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of 12-LOX and COX-2 reduces the proliferation of human epidermoid carcinoma cells (A431) by modulating the ERK and PI3K-Akt signalling pathways.
Agarwal S; Achari C; Praveen D; Roy KR; Reddy GV; Reddanna P
Exp Dermatol; 2009 Nov; 18(11):939-46. PubMed ID: 19558494
[TBL] [Abstract][Full Text] [Related]
17. The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPARgamma. Influence of albumin.
López-Parra M; Clària J; Titos E; Planagumà A; Párrizas M; Masferrer JL; Jiménez W; Arroyo V; Rivera F; Rodés J
J Hepatol; 2005 Jan; 42(1):75-81. PubMed ID: 15629510
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous inhibition of COX-2 and 5-LOX activities augments growth arrest and death of premalignant and malignant human lung cell lines.
Schroeder CP; Yang P; Newman RA; Lotan R
J Exp Ther Oncol; 2007; 6(3):183-92. PubMed ID: 17552358
[TBL] [Abstract][Full Text] [Related]
19. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.
Shin DM; Zhang H; Saba NF; Chen AY; Nannapaneni S; Amin AR; Müller S; Lewis M; Sica G; Kono S; Brandes JC; Grist WJ; Moreno-Williams R; Beitler JJ; Thomas SM; Chen Z; Shin HJ; Grandis JR; Khuri FR; Chen ZG
Clin Cancer Res; 2013 Mar; 19(5):1244-56. PubMed ID: 23422093
[TBL] [Abstract][Full Text] [Related]
20. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.
Zhang X; Chen ZG; Choe MS; Lin Y; Sun SY; Wieand HS; Shin HJ; Chen A; Khuri FR; Shin DM
Clin Cancer Res; 2005 Sep; 11(17):6261-9. PubMed ID: 16144930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
